Clinical trial / 2007
In rheumatoid arthritis patients, 12 weeks of glucosamine improved pain and symptom evaluations but showed no effect on conventional antirheumatic measures.
A randomized placebo-controlled trial evaluated daily administration of 1,500 mg glucosamine hydrochloride versus placebo for 12 weeks alongside conventional medication in 51 rheumatoid arthritis patients. Significant improvements were not observed for joint counts, ACR20 responder rates, ESR, or CRP levels. However, the face scale and visual analogue scale for pain significantly favored the glucosamine group, and serum MMP-3 levels decreased. Patient self-evaluations and physician global evaluations showed noticeable symptom improvements, leading authors to conclude that glucosamine seemed to exert some symptomatic effects without conventional antirheumatic effects.
- Study type
- Randomized placebo-controlled trial
- Who was studied
- 51 rheumatoid arthritis patients (25 in the glucosamine group, 26 in the placebo group)
- What was measured
- Joint counts, ACR20 responders, face scale, visual analogue scale pain, ESR, CRP, serum MMP-3 levels, patient and physician evaluations
THE PAPER
Effects of glucosamine administration on patients with rheumatoid arthritis.
Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Rheumatol Int, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.